Skip to main content
. Author manuscript; available in PMC: 2023 Mar 23.
Published in final edited form as: Neuropsychology. 2019 Jan 28;33(3):417–424. doi: 10.1037/neu0000506

Table 1.

Clinical and Demographic Characteristics

Characteristic SCZ/SCAD (n = 51) BPAD (n = 23) MDD (n = 43) HC (n = 88)
Age M (SD)   43.6 (12.7) 46.6 (12.4)   44.3 (13.6)   35.6 (10.4)
Sex (male) n (%)   33 (64.7)    12 (52.2)   22 (51.2)   40 (45.5)
Current substance abuse n (%)     1 (2.0)   1 (4.3)     5 (11.6)     0 (.0)
Current antipsychotic use n (%)   45 (88.2)    15 (65.2)     9 (20.9)     0 (.0)
Smoking status n (%)   13 (25.5)   7 (30.4)   10 (23.3)     3 (3.4)
Race
 Caucasian n (%)   37 (72.5)    18 (78.3)   35 (81.4)   63 (71.6)
 African American n (%)     6 (11.8)   4 (17.4)     4 (9.3)   10 (11.4)
 Asian n (%)     5 (9.8)   1 (4.3)     3 (7.0)   10 (11.4)
 American Indian/Alaskan n (%)     2 (3.9)   0 (.0)     1 (2.3)     1 (1.1)
 Other n (%)     1 (2.0)   0 (.0)     0 (.0)     4 (4.5)
Clinical measure M (SD)
 IQ   92 (14.1)    96 (18.7) 105.8 (18) 107.7 (15.5)
 PANSS–Positive 16.04 (6.2)
 PANSS–Negative   22.8 (5.2)
 PANSS–General   31.9 (6.7)
 PANSS–Total score   70.8 (14.7)
 IDS-SR   16.5 (12.1) 30.2 (17.5)   26.9 (15.5)  4.0 (3.7)
 Lnh   1.07 (2.19) 1.84 (2.33) .84 (1.94)  .40 (1.28)

Note. SCZ/SCAD = schizophrenia/schizoaffective disorder; BPAD = bipolar affective disorder; MDD = major depressive disorder; HC = healthy control; IQ = intelligence quotient; PANSS = Positive and Negative Syndrome Scale; IDS-SR = Inventory of Depressive Symptomatology–Self-Report; Lnh = the natural log of the hyperbolic discounting rate for probability, h.